Academic Journals Database
Disseminating quality controlled scientific knowledge

Efficacy and safety of glycoprotein IIb/IIIa blocker monofram in coronary stenting in patients with acute myocardial infarction

ADD TO MY LIST
 
Author(s): E.I. Makhiyanova | A.S. Galyavich

Journal: Racionalʹnaâ Farmakoterapiâ v Kardiologii
ISSN 1819-6446

Volume: 7;
Issue: 4;
Start page: 452;
Date: 2011;
Original page

Keywords: acute myocardial infarction | coronary stenting | monafram.

ABSTRACT
Aim. To study of efficacy and safety of glycoprotein IIb/IIIa blocker monafram in acute ST-segment elevation myocardial infarction (STEMI) patients, underwent coronary stenting.Material and methods. 220 STEMI patients were included in the trial; they were split into two groups. 109 patients of the first group were underwent coronary stenting with i/v monafram therapy. Coronary stenting without monafram therapy was performed in 111 patients of the second group. Bare metal stents were used in all patients. Deaths, stent thrombosis, individual intolerance, allergic reactions, bleeding were registered during hospitalization.Results. There were 3 (2.75%) cases of stent thrombosis in monafram group and 4 (3.6%) ones - in the control group. Good tolerance of monafram was observed in all patients. There were no allergic reactions, major and minor bleedings. Reinfarction rate was similar in both groups during 30 days observational period.Conclusions. Monafram therapy is effective and safe in acute STEMI patients underwent coronary stenting.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?